CDMO Tedor Pharma recapitalizes following multi-million dollar investment

By Melissa Fassbender contact

- Last updated on GMT

(Image: ozayo)
(Image: ozayo)
The newly-formed investment firm DORA Ventures has recapitalized Tedor Pharma, which recently completed a multi-million-dollar expansion of its manufacturing capabilities.

Tedor Pharma is a contract development and manufacturing company (CDMO) founded in 2001.

The company yesterday announced the closing of the recapitalization and reorganization of its business funded by investments from DORA Ventures, which is owned and controlled by Laura Iorio, chairwoman of Tedor Pharma, and Doug Drysdale, president and CEO of Tedor Pharma.

"The recapitalization was undertaken to give Tedor a strong operating runway,"​ Drysdale told us. "The next steps for Tedor are to leverage the capital investments made over the past two years to expand production capacity."

The Cumberland, RI-based CDMO recently completed a multi-million-dollar expansion of its large-scale manufacturing capabilities. The investment included the installation of new multi-purpose cGMP manufacturing suites.

"We are already seeing an increase in volumes and projects from existing customers and our business development efforts continue to create new opportunities,​" Drysdale said.

Related news

Show more

Related products

show more

Facilities: Grangemouth, UK

Facilities: Grangemouth, UK

Piramal Pharma Solutions | 28-Jun-2021 | Insight Guide

The Piramal Pharma Solutions site in Grangemouth, UK offers development, clinical & commercial scale manufacture of bio-conjugates including Antibody...

Facilities: Aurora, Canada

Facilities: Aurora, Canada

Piramal Pharma Solutions | 28-Jun-2021 | Insight Guide

The Piramal Pharma Solutions facility in Aurora Canada offers development, clinical and commercial GMP manufacturing of Active Pharmaceutical Ingredients...

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Related suppliers

Follow us

Products

View more

Webinars